CN114615975A - 欧当归内酯a在制备治疗或预防肾病药物中的用途 - Google Patents

欧当归内酯a在制备治疗或预防肾病药物中的用途 Download PDF

Info

Publication number
CN114615975A
CN114615975A CN201980101841.2A CN201980101841A CN114615975A CN 114615975 A CN114615975 A CN 114615975A CN 201980101841 A CN201980101841 A CN 201980101841A CN 114615975 A CN114615975 A CN 114615975A
Authority
CN
China
Prior art keywords
group
renal
mice
kidney
model
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980101841.2A
Other languages
English (en)
Other versions
CN114615975B (zh
Inventor
韩力
黄学石
李莉娅
努尔比耶·奥布力喀斯木
王占友
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liaoning Shuangshili Pharmaceutical Technology Co ltd
Original Assignee
Liaoning Shuangshili Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liaoning Shuangshili Pharmaceutical Technology Co ltd filed Critical Liaoning Shuangshili Pharmaceutical Technology Co ltd
Publication of CN114615975A publication Critical patent/CN114615975A/zh
Application granted granted Critical
Publication of CN114615975B publication Critical patent/CN114615975B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

属于医药技术领域，涉及治疗慢性肾脏病的药物，特别涉及含有欧当归内酯A(Levistolide A或Diligustilide，C21)的药物组合物及其应用。C21能用于预防和治疗包括但不限于糖尿病(DM)、高血压(HT)、肾小球肾炎(GN)、代谢综合征、泌尿系统疾病等多种原因导致的慢性肾脏系统疾病。

Description

PCT国内申请，说明书已公开。

Claims (7)

  1. PCT国内申请，权利要求书已公开。
CN201980101841.2A 2019-12-11 2019-12-11 欧当归内酯a在制备治疗或预防肾病药物中的用途 Active CN114615975B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/124464 WO2021114125A1 (zh) 2019-12-11 2019-12-11 欧当归内酯a在制备治疗或预防肾病药物中的用途

Publications (2)

Publication Number Publication Date
CN114615975A true CN114615975A (zh) 2022-06-10
CN114615975B CN114615975B (zh) 2023-08-08

Family

ID=76329152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980101841.2A Active CN114615975B (zh) 2019-12-11 2019-12-11 欧当归内酯a在制备治疗或预防肾病药物中的用途

Country Status (2)

Country Link
CN (1) CN114615975B (zh)
WO (1) WO2021114125A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113616640B (zh) * 2021-08-19 2023-03-17 广州医科大学附属第二医院 欧当归内酯a在制备抗心梗后心室重构的药物中用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557391A (zh) * 2004-01-13 2004-12-29 合肥恒星药物研究所 一种治疗慢性肾炎病的中药
CN104706633A (zh) * 2013-12-17 2015-06-17 上海中医药大学 欧当归内酯A以及类似物抑制Syk激酶活性的用途
CN103857391B (zh) * 2011-09-30 2016-06-08 沈阳蓝桑医药生物技术研发有限公司 含有瑞利格内酯的药物组合物及其应用
CN108210651A (zh) * 2018-04-10 2018-06-29 新乡医学院 一种用于治疗糖尿病肾病的天然药物组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107273A1 (en) * 2005-04-06 2006-10-12 National University Of Singapore Compounds having progestogenic activity and their use
CN102772400A (zh) * 2012-01-12 2012-11-14 上海中医药大学 欧当归内酯a的医药用途
CN102631387A (zh) * 2012-04-24 2012-08-15 天津大学 一种治疗心脑血管病的川芎内酯类成分制剂及其制备方法
CN108078978A (zh) * 2018-01-16 2018-05-29 山西大学 欧当归内酯a在制备肿瘤化疗药物增敏剂中的应用
CN110057958B (zh) * 2019-05-21 2021-03-02 南开大学 通过检测当归药材中具有钙拮抗功效的有效成分含量评价质量等级的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557391A (zh) * 2004-01-13 2004-12-29 合肥恒星药物研究所 一种治疗慢性肾炎病的中药
CN103857391B (zh) * 2011-09-30 2016-06-08 沈阳蓝桑医药生物技术研发有限公司 含有瑞利格内酯的药物组合物及其应用
CN104706633A (zh) * 2013-12-17 2015-06-17 上海中医药大学 欧当归内酯A以及类似物抑制Syk激酶活性的用途
CN108210651A (zh) * 2018-04-10 2018-06-29 新乡医学院 一种用于治疗糖尿病肾病的天然药物组合物及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
林燕;曹永龙;: "肾络宁干预糖尿病肾病大鼠病变进展研究" *
罗永明，张金海，潘家祜，李其生: "茶芎中两个二聚苯酞类化合物的分离和鉴定" *
莫之准: "川芎、当归超临界CO2萃取物改善衰老小鼠肝肾损伤研究" *
董晴;陈明苍;: "当归化学成分及药理作用研究进展" *

Also Published As

Publication number Publication date
CN114615975B (zh) 2023-08-08
WO2021114125A1 (zh) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2003260985B2 (en) Extraction and purification method of active constituents from stem of Lonicera japonica Thunb., its usage for anti-inflammatory and analgesic drug
WO2021249420A1 (zh) 血筒素在制备抗类风湿关节炎药物中的应用
JP4951530B2 (ja) 腎障害治療用薬剤組成と薬草抽出物含有の健康食品
CN114615975B (zh) 欧当归内酯a在制备治疗或预防肾病药物中的用途
Zhu et al. Rehmannia glutinosa Libosch and Cornus officinalis Sieb herb couple ameliorates renal interstitial fibrosis in CKD rats by inhibiting the TGF-β1/MAPK signaling pathway
CN107349244B (zh) 丙二酰基人参皂苷的提取方法
CN111803488A (zh) 白术内酯ⅱ在制备抗肾纤维化药物中的应用及抗肾纤维化药物
Zhang et al. Centella asiatica inhibits renal interstitial fibrosis by regulating Smad3 and Smad7 expression in the TGFβ signaling pathway
CN112057510B (zh) 栀子提取物在制备治疗溃疡性结肠炎药物中的应用
CN113893301A (zh) 治疗肾虚血瘀证型骨质疏松的中药制剂及其制备方法
CN109512962B (zh) 一种用于器脏纤维化的中药组合物及其制备方法和应用
CN112807319A (zh) 曲札茋苷在治疗小肠缺血再灌注损伤中的应用
CN103054976B (zh) 一种治疗血小板减少症的中药组合物及其制备方法和应用
WO2022228095A1 (zh) 南山花根提取物在制备治疗肺纤维化的药物中的应用
CN115252631B (zh) 三七提取物在制备治疗糖尿病肾病药物中的应用
WO2015049553A1 (en) Effect of garcinol in delaying the progression of diabetic nephropathy
CN114306350B (zh) 胆固醇硫酸盐在制备预防脓毒症的药物中的用途
EP4023238A1 (en) Use of liriodendron chinense (hemsl.) sarg or extract thereof in preparation of medicine for reducing serum uric acid level and preventing and treating uric acid nephropathy
CN113456684B (zh) 滨蒿用于制备治疗肺纤维化的药物的用途
CN117414372A (zh) N6-甲基腺苷及其n6-氘代甲基腺苷类化合物在制备防治肾小球局灶硬化肾病药物中的应用
CN117752721A (zh) 橘叶水提物及其在制备预防胃溃疡药物和保健品中的应用
CN118105445A (zh) 高良姜提取物在制备防治肾损伤的药物中的应用
CN117942332A (zh) 鼠尾草酚在制备治疗或缓解顺铂诱导的急性肾损伤的药物中的应用
CN113230294A (zh) 菴闾中总香豆素及制备方法和其药物用途
CN116966257A (zh) 莪术油在制备改善顺铂诱导的急性肾损伤的药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant